BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Boston Biomedical Research Institute Scientists Discover Promising New Therapeutic Target For Heart Disease


7/11/2006 10:22:24 AM

WATERTOWN, Mass., July 10 /PRNewswire/ -- In the July 2006 edition of the American Journal of Physiology -- Heart and Circulatory Physiology, scientists at the Boston Biomedical Research Institute identified Puma (p53 upregulated modulator of apoptosis) as a potential new target for the therapeutic intervention of heart disease. In recognition of the possible clinical ramifications of this work and the scientific communities' interest in the search for novel therapeutics, the American Journal of Physiology also released an editorial review focusing on this study and the role of Puma in heart disease.

Heart disease is the leading cause of morbidity for both men and women in the United States, and the demand for effective alternatives is high. In their study, Dr. Ambrus Toth, Dr. Phil Nickson, and their principle investigator Dr. Peter Erhardt, all of the Boston Biomedical Research Institute, described how the targeted removal of Puma -- a recently discovered cellular protein involved in the promotion of programmed cell death, otherwise known as apoptosis -- protects hearts against the damage caused by myocardial infarction. Based on these observations, Dr. Toth and his colleagues propose that specifically blocking the activity of Puma in the heart could promote the recovery of heart disease patients.

In the American Journal of Physiology editorial review, Dr. Keith Webster recognizes the importance of Puma in heart disease and compares it to other candidate therapeutic targets, such as BNIP3 and Noxa. Dr. Webster also speculates on how emerging data may be connected, and how they should be advanced from scientific observations to viable therapeutics.

Dr. Charles Emerson, director of Boston Biomedical, is extremely pleased that the importance of Dr. Toth's work has been recognized, saying, "This success is a great example of how the pursuit of scientific concepts can lead to the development of novel therapeutics."

The Boston Biomedical Research Institute is a not-for-profit institution dedicated to the understanding, treatment, and prevention of specific human diseases such as cardiovascular disease, cancer, diabetes, and Alzheimer's disease. For more information visit us on the web at http://www.BBRI.org.

Boston Biomedical Research Institute

CONTACT: Terence McGowan of Boston Biomedical Research Institute,+1-617-658-7707, mcgowan@bbri.org



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES